Anna graduated with a BSc in Molecular Biology from the University of Warsaw, before carrying out an MSc project aimed at studying the molecular basis of male intellectual disability at the National Research Institute of Mother and Child in Warsaw. As part of her master’s degree she spent a year abroad, first as a Socrates-Erasmus scholar at Manchester University, then at the University of Verona on a scholarship from the Italian Ministry of Foreign Affairs, and finally as a FEBS scholar at the European Molecular Biology Laboratory in Monterotondo. Subsequently, she did her PhD in Developmental Biology at the Wellcome Trust Sanger Institute at Cambridge University, investigating Monosomy 21 and Sotos Syndrome mouse models, with the aim of unravelling the pathophysiology of these human genomic disorders. Next, Anna joined the Department of Clinical Neurosciences at UCL as a postdoctoral research associate, leading two research projects, the first designed to determine the role of glucocerebrosidase 1 (Gba1) mutations in the development of Parkinson’s disease, and the second aimed at investigating the potential of the molecular chaperone ambroxol as a putative drug for treatment of Parkinson’s disease. Anna joined the Complex Disease Epigenetics Group in February 2018 to work on the MRC project investigating regulatory genomic variation associated with schizophrenia in human neuronal nuclei.
https://www.epigenomicslab.com/wp-content/uploads/2018/03/AnnaPicture-234x300.jpg 300 234 Jonathan Mill /wp-content/uploads/2015/06/Complex-Disease-Epigenetics-Group.png Jonathan Mill2018-03-05 10:56:192018-03-05 11:49:22Anna Migdalska-Richards